Impact of expanded access to combination antiretroviral therapy in pregnancy: results from a cohort study in Ukraine

Bailey, Heather; Townsend, Claire L; Semenenko, Igor; Malyuta, Ruslan; Cortina‐Borja, Mario; Thorne, Claire

doi:10.2471/blt.12.114405

Cited by 21 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the UK, most pregnant women with HIV are diagnosed and 99% of these now receive cART, whereas UNAIDS estimates that coverage with effective regimens for PMTCT is only 27% in west and central Africa [39]. Meanwhile, MTCT rates in parts of eastern Europe are four to 10 times higher than in the UK, reflecting poorer access to cART and the challenges of delivering optimal PMTCT services to socially disadvantaged women such as injecting drug users [9].…”

Section: Duration Of Combination Antiretroviral Therapy 2000-2011mentioning

confidence: 97%

“…In those starting cART in pregnancy and with information available (18/21), median duration of cART was 12.9 weeks (IQR 4. [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. Median maternal viral load was 712 copies/ml (IQR 194-19 214 copies/ml, n ¼ 20) at a median 13.5 days before delivery (IQR 0.5-23.5).…”

Section: Mother-to-child Hiv Transmission In 2007-2011mentioning

confidence: 99%

“…These interventions have resulted in dramatic reductions in MTCT, and many countries in northern and western Europe have already achieved rates of less than 2% [3][4][5][6], in line with the WHO goal for virtual elimination of MTCT in the European region by 2015 [7]. Rates in eastern European countries remain higher, although there has also been significant progress [8,9]. In the UK, success in preventing MTCT has resulted from high uptake of antenatal HIV screening (around 97%) [1,10], effective national guidelines [11], and a coordinated multidisciplinary approach to the management of HIV-positive pregnant women, involving obstetric, HIV, and pediatric services within the National Health Service.…”

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011

Townsend

Byrne

Cortina‐Borja

et al. 2014

Aids

Self Cite

350

197

View full text Add to dashboard Cite

show abstract

Section: Duration Of Combination Antiretroviral Therapy 2000-2011mentioning

confidence: 97%

Section: Mother-to-child Hiv Transmission In 2007-2011mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011

Townsend

Byrne

Cortina‐Borja

et al. 2014

Aids

Self Cite

350

197

View full text Add to dashboard Cite

show abstract

“…A Ukraine site has also been established and provides data from a lower resource setting within Europe [69]. …”

Section: Art Safety Surveillance Programsmentioning

confidence: 99%

Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges

Zash

Williams

Sibiude

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction The use of antiretroviral therapy (ART) in pregnancy to prevent vertical HIV transmission has been one of the most successful public health programs in the last decade. As a result, an unprecedented number of women are taking ART at conception and during pregnancy. Given few randomized studies evaluating safety of different ART regimens in pregnancy, ongoing drug safety surveillance is critical. Areas Covered This review aims to provide a rationale for ART drug safety surveillance, describe changing patterns of ART use and summarize current surveillance efforts in both low-resource and high-resource settings. Additionally, biostatistical approaches to and challenges in analysis of observational surveillance data are discussed. Expert Opinion The global landscape of ART use in pregnancy is rapidly increasing and evolving. Any increase in adverse effects of in-utero exposure to ART has the potential to reduce the impact of improvements in infant morbidity and mortality gained from decreased vertical HIV transmission. ART drug safety surveillance should therefore be a critical piece of programs to prevent mother to child transmission in both high- and low-resource settings. Current surveillance efforts could be strengthened with long-term follow-up of exposed children, pooling of data across cohorts and standardized approaches to analysis.

show abstract

“…These results are encouraging compared with previous sero-surveillance data in Burkina Faso, where the estimated percentage of children infected with HIV through vertical transmission from their HIV-positive mothers who have given birth in the last 12 months in2013, 2014, 2015 was 5.72%, 5.30% and 4.95%,respectively (10). In other countries such as China, the vertical transmission rate was reported as 6.7% in 2013 (11) and in Ukraine in 2010 it was reported as 4.1% (12), despite the implementation of PMTCT programs. In addition, similar vertical transmission rates have been reported in other countries, particularly South Africa, where surveys conducted in 2010 and 2011 revealed vertical transmission rates of 3.5% and 2.7%, respectively (13).…”

Section: Discussionmentioning

confidence: 99%

Residual mother-to-child transmission of HIV in Burkina Faso

Ba¹,

Sanou²,

Tamini³

et al. 2017

Af J Clin Exp Micro

View full text Add to dashboard Cite

104Résultats : Au total 186 femmes enceintes ont été enregistrées dans l'ensemble des sites de l'étude dont l'âge moyen était de 29,17 ans avec un écart type de ± 6,13. A partir des enfants nés de ces femmes, 430 DBS ont effectivement bénéficié d'un examen PCR soit 91,1% de taux de réalisation de PCR. A la suite des analyses six (06) enfants étaient porteurs de VIH1 soit 1,3% de la population d'enfants testés. Le statut sérologique du bébé était associé au mode de délivrance (p = 0,000), à l'administration de médicaments antirétroviraux à la mère après l'accouchement (p = 0,0064), à l'administration de la névirapine au nouveau-né à la naissance (p = 0,022), à l'utilisation de méthodes contraceptives après l'accouchement (p = 0,028) et à la présence des affections/infections au sein depuis l'accouchement (p = 0,013).Conclusion: Les résultats de notre étude sont encourageants et démontrent que l'efficacité des interventions dans le programme de prévention de la transmission mère l'enfant (PTME) pour les femmes enceintes séropositives peut être améliorée par l'initiation précoce de la trithérapie au début de la grossesse et l'amélioration de l'observance des antirétroviraux (ARV).

show abstract

Impact of expanded access to combination antiretroviral therapy in pregnancy: results from a cohort study in Ukraine

Cited by 21 publications

References 26 publications

Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011

Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011

Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges

Residual mother-to-child transmission of HIV in Burkina Faso

Contact Info

Product

Resources

About